Zyflo
Links shared publicly online about this topic
New Precautions For Singulair, Accolate, And Zyflo
asthma.about.com — “New Precautions For Singulair, Accolate, And Zyflo” View full resource at asthma.about.com
Most Recently Shared on September 4, 2009 at 11:37 am By:
Pat Internist, Physician, Doctor, and Pediatrician
New Precautions For Singulair, Accolate, And Zyflo #asthma #health #allergies http://bit.ly/2tbFgw
FDA Alert: Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)
drugs.com — “FDA Alert: Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)” View full resource at drugs.com
Most Recently Shared on June 13, 2009 at 1:40 am By:
FDA Alert - Leukotriene Inhibitors for Asthma Get 'Precaution' Labeling for Possible Neuropsychiatric Events - http://bit.ly/9q3LW
FDA Alert: Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)
drugs.com — “FDA Alert: Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)” View full resource at drugs.com
Most Recently Shared on August 29, 2009 at 7:07 pm By:
FDA Alert - Update on Leukotriene Inhibitors: Precaution Labeling for Possible Neuropsychiatric Events - http://bit.ly/SjR6o
Cornerstone gets FDA warning on Zyflo CR marketing | Pharmaceutical Processing
pharmpro.com — “FDA warns Cornerstone about incomplete and misleading website and visual aid for asthma drug” View full resource at pharmpro.com
Most Recently Shared on July 7, 2010 at 12:58 am By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Cornerstone gets FDA warning on Zyflo CR marketing | Pharmaceutical Processing http://is.gd/di3g9
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on June 7, 2010 at 3:35 pm By:
Internal Medicine Medical School
RT @JanCernyMDPhD New study targeting CML stem cells: http://clinicaltrials.gov/ct2/show/NCT01130688
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on August 4, 2011 at 3:49 pm By:
JanCerny, MD, PhD Hematologist, Physician, Doctor, PhD, Internist, and Oncologist
Clinical study in CML opened. http://ow.ly/5VdTa
Controversy Around Suicidality Monitoring At Clinical Trials In Optimising Clinical Development In CNS, London, 15-16 March 2011
medicalnewstoday.com — “The absence of suicidality monitoring in previous clinical trials has lead to a number of controversies beyond those surrounding Prozac. There has been continued discussion of a link between anti” View full resource at medicalnewstoday.com
Most Recently Shared on November 29, 2010 at 2:14 pm By:
MNT Clinical Trials Health News
Controversy Around Suicidality Monitoring At Clinical Trials In Optimising Clinical Development In CNS, London, 15-16 ... http://mnt.to/3NcN
Asthma Drugs Get 'Precaution' Labeling for Possible Psychiatric Side Effects - m
myoptumhealth.com — “Read the news article Asthma Drugs Get 'Precaution' Labeling for Possible Psychiatric Side Effects at www.myOptumHealth.com” View full resource at myoptumhealth.com
Most Recently Shared on June 13, 2009 at 2:22 am By:
Asthma Drugs Get 'Precaution' Labeling for Possible Psychiatric Side Effects: FDA says users of Singulair and si.. http://tinyurl.com/lhm679
Leukotriene modifier drug label change requested by FDA - MPR
empr.com — “The FDA has requested that manufacturers of leukotriene modifiers include a precaution in the drug labeling regarding neuropsychiatric events that have been reported in some patients taking montelukast (Singulair, from Merck), zafirlukast (Accolate, from AstraZeneca) and zileuton (Zyflo CR from Cornerstone Therapeutics).” View full resource at empr.com
Most Recently Shared on June 16, 2009 at 6:39 pm By:
MPR News: Leukotriene modifier drug label change requested by FDA: The FDA has requested that manufactu.. http://tinyurl.com/nbs7rz
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
Advertisement
